WP
AURA icon

Woodline Partners’s Aura Biosciences AURA Stock Holding History

Woodline Partners’s Portfolio AURA Stock Details AURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.59M Buy
+1,210,183
New +$8.66M 0.03% 568

Other funds holding AURA

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Woodline Partners's AURA Position: Q2 2026 in Review

Woodline Partners opened a new position in Aura Biosciences (AURA) in Q2 2026: 1,210,183 shares worth $8.59M. The stake represents 0.03% of the portfolio and ranks #568 among its holdings.

147 funds tracked by Wall St. Rank hold AURA as of Q2 2026.

  • Woodline Partners held 1,210,183 shares of Aura Biosciences worth $8.59M as of Q2 2026.
  • Aura Biosciences was a new Woodline Partners position in Q2 2026.
  • Aura Biosciences made up 0.03% of Woodline Partners's portfolio in Q2 2026, its #568 holding.
  • 147 funds tracked by Wall St. Rank held Aura Biosciences as of Q2 2026.

Based on Woodline Partners's 13F filing for Q2 2026, filed 14 Aug 2026.